Patent · US Active

Compounds

US9409870B2 · kind B2 · utility

4Cited by
0References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 27, 2015
Grant dateAug 9, 2016
Priority date
Expiry dateNov 27, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D405/14
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.